Indeed, CD8+ T cells specific to conserved viral epitopes correlate with protection against symptomatic influenza illness, making a vaccine capable of stimulating heterologous CD8+ T cells an attractive target in vaccine design (5–9). This evidence concerns the gene CD8A and influenza.